Marijuana’s legal headway in recent years has paved the way for new interest in remedies typically relegated to the black market. Companies that work with drugs like psilocybin, an ingredient in magic mushrooms, or Ibogaine, used in ayahuasca-style ceremonies, are proliferating, with early-stage investors predicting such substances have an even better shot than cannabis at disrupting the $70 billion market for mental health. The question now is whether such aims ...
Dec. 11, 2020, 7:46 PM
Psychedelics Replace Pot as the New Favorite Edgy Investment (1)

Tiffany Kary
Bloomberg News